Neos Therapeutics is a pharmaceutical company that utilizes its modified-release drug delivery platform for the treatment of attention deficit hyperactivity disorder, or ADHD. Its products and product candidates are extended-release in orally disintegrating tablets or liquid suspension dosage forms. Its lead asset, Adzenys XR-ODT, was approved by the FDA on January 27, 2016 as the first amphetamine XR-ODT for the treatment of ADHD on the market. Subsequently, the drug was launched in the United States in May 2016. The Company also possesses other ADHD assets, Cotempla XR-ODT and NT-0201. Cotempla XR-ODT, if approved, will be the first methylphenidate XR-ODT for ADHD on the market.
Neos Therapeutics is a pharmaceutical company that utilizes its modified-release drug delivery platform for the treatment of attention deficit hyperactivity disorder, or ADHD. Its products and product candidates are extended-release in orally disintegrating tablets or liquid suspension dosage forms. Its lead asset, Adzenys XR-ODT, was approved by the FDA on January 27, 2016 as the first amphetamine XR-ODT for the treatment of ADHD on the market. Subsequently, the drug was launched in the United States in May 2016. The Company also possesses other ADHD assets, Cotempla XR-ODT and NT-0201. Cotempla XR-ODT, if approved, will be the first methylphenidate XR-ODT for ADHD on the market.